Life science tools market seen reaching $379.95 billion by 2030

The life science tools market is projected to rise from $201.37 billion in 2025 to $229.1 billion in 2026, then climb to $379.95 billion by 2030. Growth is being driven by biopharmaceutical demand, automation, genomics spending and wider use in diagnostics and drug discovery.

Why it matters: - Life science tools sit at the center of biotech, pharmaceutical research and clinical innovation. - Faster growth in this market points to more demand for instruments, reagents, consumables and digital lab systems across research and production workflows. - The expansion also tracks with rising biopharmaceutical output and the push for more precise testing and quality control.

What happened: - The Business Research Company released its Life Science Tools Global Market Report 2026 on Aug. 13, 2026. - The report puts the market at $201.37 billion in 2025 and $229.1 billion in 2026. - The report forecasts the market will reach $379.95 billion by 2030. - North America was the largest regional market in 2025. - Asia-Pacific is expected to be the fastest-growing region through the forecast period. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available here. - The full report is available here.

The details: - The market grew in the past few years on the back of traditional lab instruments, limited access to high-quality reagents and consumables, and heavy use of manual laboratory methods. - Pharmaceutical and biotech research activity also supported demand. - Academic and research institution growth added to the market base. - The forecast period is expected to benefit from automation and smart laboratory equipment. - Investment in genomics and proteomics research is a major demand driver. - Personalized medicine is adding more use cases for life science tools. - Clinical diagnostics and drug discovery are expanding the market’s application range. - Cloud-based data analytics and digital lab solutions are improving efficiency and innovation. - Expected trends include high-throughput instruments, more advanced consumables and reagents, growth in genomic, proteomic and cell biology research, stronger demand from contract research organizations, and better quality control and calibration services. - Life science tools include specialized equipment and systems used to study living organisms and their biological functions. - These tools support molecular biology, genetics, pharmacology and clinical research. - Biopharmaceuticals such as proteins, antibodies and vaccines are a key growth engine because they address chronic and complex diseases. - Life science tools support research, testing, manufacturing and quality control for biologics production. - Cardinal Health said the US FDA had approved 33 biosimilar products as of January 2022, with 21 available on the market. - Cardinal Health also said FDA approvals rose to 40 by 2023, with 25 commercially accessible. - The report highlights new 2026 additions including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - The report suggests the market is shifting from basic lab hardware toward more automated, data-driven and service-heavy workflows. - The emphasis on personalized medicine and biologics indicates higher demand for specialized tools rather than one-size-fits-all platforms. - North America’s lead and Asia-Pacific’s faster growth point to a market split between established research hubs and expanding infrastructure markets.

What's next: - More adoption of smart labs, digital analytics and high-throughput systems is likely to shape purchasing decisions. - Biopharmaceutical expansion should continue to support demand for testing, validation and quality control tools. - Faster growth in Asia-Pacific may increase competition among global suppliers and raise investment in regional lab infrastructure. - The report’s forecasting dashboards and market scoring tools are positioned to help vendors and investors target the most attractive segments.

The bottom line: - Life science tools are moving deeper into a growth phase fueled by automation, biologics and data-driven research, with the market forecast to nearly double from 2025 to 2030.